#204 NephMadness 2020: SGLT2 Inhibitors
Apr 06, 2020•50 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients. Show Notes | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com
Credits
- Written and Produced by: Hannah R. Abrams
- Cover Art and Infographic by: Hannah R. Abrams
- Hosts: Hannah R Abrams, Matthew Watto MD, FACP
- Editor: Clair Morgan of Nodderly.com (audio), Emi Okamoto MD (written)
- Guests: Harish Seethapathy MD; Matthew Sparks MD; Joel Topf MD
Sponsor: McGraw Hill
Time Stamps
-
00:00 Sponsor
-
00:26 Intro, disclaimer, guest bio
-
02:57 Guest one-liner and Picks of the Week*: Michael Pollan audiobook on Coffee and Caffeine Addiction
-
03:52 SGLT2i definition, background, and why we now consider CV endpoints in diabetes
-
11:16 Sponsor
-
12:00 Tubuloglomerular feedback; Balloon analogy
-
17:40 Other mechanisms for SGLT2i
-
23:05 Back to the case; Risks from SGLT2i; Counseling and Monitoring
-
34:18 SGLT2i for non-diabetic kidney disease; Possible mechanisms: Joel’s caution against early adoption
-
41:42 SGLT2 inhibitors in kidney transplant
- 45:20 Take home points and picks for the SGLT2 inhibitor region
- 49:50 Outro
For the best experience, listen in Metacast app for iOS or Android